Novocure Q3 net revenues $127.3M (-3% YoY); net loss $49.5M as INNOVATE-3 misses endpoint

NovoCure Ltd

2023-Q3 EPS reported -$1.51 revenue$375,554,000

Net revenues $127.3M, down 3% YoY; US contributed $86.2M, Germany $14.7M, Japan $7.6M.
Net loss $49.5M ($0.46 loss per share); adjusted EBITDA $(29.1)M.
3,639 active patients on therapy as of Sept 30, 2023; prescriptions up 6% YoY to 1,467.
Phase 3 INNOVATE-3 (ovarian cancer) did not meet primary overall survival endpoint at final analysis.
Cash & short-term investments $921.2M; gross margin 75%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NovoCure Ltd reported the quarter ended September 30, 2023 results: revenue $127.3 million, net income Net loss for the quarter was $49.5 million with loss per share of $0.46, EPS $0.46.

Period: the quarter ended September 30, 2023
Revenue: $127.3 million
Net income: Net loss for the quarter was $49.5 million with loss per share of $0.46
EPS: $0.46
Result: reported results

Exact text from the filing

Total net revenues for the quarter were $127.3 million, a decrease of 3% compared to the same period in 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-23-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.